Search Results

Biosimilars

Patient Access Barriers in 2025 and Beyond

The landscape of patient access has become increasingly complex, intensified by evolving channel dynamics, greater biosimilar investment, and legislative reform. As payers evolve their utilization management tactics, manufacturers must also become more sophisticated in their access strategies. To explore these topics, MMIT and The Dedham Group conducted the second annual
© 2024 MMIT

Increased Competition Drives Biosimilar Market Shifts

For the past decade, biosimilar adoption in the U.S. has proceeded at a relatively slow pace, due in large part to limited financial rebates for payers and provider preferences for biologics. Recent research suggests that utilization is finally picking up steam as more health plans place both biosimilars and their
© 2024 MMIT

Key Benefits of Early Market Access Planning

According to our 2024 State of Patient Access survey, 81% of pharma companies are launching their market access planning much earlier than they did five years ago. By Phase I, one-third of pharma companies are already engaged in market access research, with most pharma companies (54%) engaged by Phase II

When Payers Become Producers: Inside the Private-Labeling Trend

Vertical integration between payers, PBMs, specialty pharmacies, and providers has grown in the last decade, with more negotiating power concentrated among a handful of major players. Now insurers are adding production arms into the mix, following CVS Health’s bid to cash in on the race for Humira biosimilar market share.

Connecting the Dots: Part D Design, the IRA, and Biosimilar Uptake

Although the biosimilar market is expected to continue growing over the next few years, adoption thus far has been somewhat slow and uneven. Recent research published in Health Affairs takes a look at how upcoming provisions of the Inflation Reduction Act (IRA) are likely to impact biosimilar coverage, concluding that
© 2024 MMIT

Cordavis Could Benefit U.S. Biosimilars Market

It has now been over a year since the first Humira biosimilar, Amgen’s Amjevita, entered the U.S. market. Eight additional adalimumab biosimilars followed suit, offering lower-cost alternatives to AbbVie’s blockbuster drug via a variety of dual-pricing and discounting strategies. Some PBMs, including Express Scripts and Optum Rx, were quick to
© 2024 MMIT

Humira Biosimilars: Pricing, Contracting and Interchangeability

This has been a significant year for the Humira (adalimumab) biosimilar market. AbbVie’s blockbuster drug Humira, an injectable used to treat a range of inflammatory conditions, saw the end of its 20-year, $200 billion monopoly in January. By the beginning of November, nine adalimumab biosimilars had made their market debut.
0 Comments Biosimilars
© 2024 MMIT

Uncovering the Patient Journey: Four Ways that Real-World Data Offers Value

For manufacturers, building a static commercialization strategy will only take you so far. But infusing that strategy with real-world data (RWD)—consisting of medical claims, lab testing and pharmacy data, and electronic health records—provides a more holistic view of the patient journey. RWD fills in crucial missing puzzle pieces, especially when
© 2024 MMIT

Navigating the U.S. Patchwork of Biosimilar Laws

The FDA approved the first biosimilar more than eight years ago, and the agency continues to give the green light to multiple agents per year. In fact, 2023 could well be a landmark year in launches, spurred by multiple biosimilars of AbbVie’s Humira (adalimumab) entering the U.S. market. While the
© 2024 MMIT

How Will the Launch of Humira Biosimilars Impact Patients, Payers and IDNs?

Across indications, biosimilar uptake is rapidly accelerating, with the number of biologics facing biosimilar competition more than doubling by 2026. This year’s impending launch of adalimumab biosimilars will serve as a case study for manufacturers, who will be studying the market’s response. Humira biosimilars have great potential to disrupt immunology